Inventiva S.A.

NASDAQ:IVA

Biotechnology

Healthcare
$3.39 +0.42%

+$0.02 today

Market cap
$176.22M
Beta
0.88
P/E (TTM)
-5.5
EPS (TTM)
-$0.56
52W Low $2.85High $7.98

Volume 3.54M

Average 0.45M

IVA Operating Cash Flow

Cash generated by the company's core business operations during the period.

Inventiva S.A.NASDAQ: IVA

Operating Cash Flow · Q4 FY2025 · quarter ended Dec 2025

Operating cash flow grows 44.4% year over year

Q4 FY2025 operating cash flow of €54.26M (cash outflow) rose 44.4% year over year. Over 3 fiscal years it compounded at +31.0% a year.

Context

  • Operating cash flow amounted to 2252.6% of revenue in FY2025, up 1318.4 pp from a year earlier.
  • Operating cash flow grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
-€54.26M— QoQ
Last fiscal yearDec 2025
-€100.98M+17.5% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+44.4%——
1 year+17.5%——
3-year CAGR+31.0%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

EUR · from the cash flow

Latest · FY2025
(100.98M) EUR
Year-over-year change
-17.5%

Operating Cash Flow vs competitors

How IVA compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +17.5% is the 3rd highest of 10, against a peer median of -12.2%.
  • Operating cash flow amounts to 2252.6% of revenue for IVA, versus a peer median of 903.8%.
IVA Competitors
Operating Cash Flow for IVA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CRBUCaribou Biosciences, Inc.LTM Mar 2026$101.25M USD-26.5%+6.9%903.8%
IVAInventiva S.A.FY2025€100.98M EUR+17.5%+31.0%2252.6%
IVVDInvivyd, Inc.LTM Mar 2026$78.72M USD-44.3%-35.8%140.9%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$72.97M USD+136.4%+32.7%4110.9%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$64.39M USD-24.2%-13.2%28616.0%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$59.69M USD+14.1%+24.4%101172.9%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$54.52M USD+0.8%+18.7%166.6%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$49.86M USD-12.2%+3.4%—
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$31.43M USD+25.2%+26.3%—
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$7.84M USD-85.9%-39.0%11.3%
Peer median (excluding IVA) —-12.2%+6.9%903.8%

Competitors are the stored peer set for IVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(49.64M)(54.27M)(110.43M)(184.21M)(340.16M)
Depreciation & Amortization(1.29M)1.7M2.6M5.2M3.22M
Deferred Income Tax(3.27M)(5.26M)(4.74M)(4.8M)(2.3M)
Stock-Based Compensation2.09M2.22M3.97M3.58M26.77M
Change in Working Capital979K5.71M17.31M1.68M6.42M
Accounts Receivables(5.32M)3.84M(5.84M)2.81M816.45K
Inventory(72K)19K(44K)417K0
Accounts Payables7.6M3.54M20M02.46M
Other Working Capital(1.23M)(1.69M)3.19M(1.54M)3.15M
Other Non-Cash Items3.5M4.98M9.68M92.63M205.07M
Operating Cash Flow(47.63M)(44.93M)(81.61M)(85.93M)(100.98M)
Capital Expenditures(534K)(561K)(540K)(333K)(237.26K)
Acquisitions (Net)89K41K000
Purchases of Investments(1.35M)(1K)(8.3M)0(127.69M)
Sales of Investments(89K)9.39M978K9.08M0
Other Investing Activities90K1K131K75.72K(1K)
Investing Cash Flow(1.79M)8.87M(7.73M)8.75M(127.93M)
Debt Repayment(28K)28.44M(4.1M)19.92M(5.98M)
Common Stock Issued25.48M8.83M28.08M57.34M237.74M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(17.73K)(772.47K)5.1M68.33M236.98K
Financing Cash Flow25.45M37.27M29.08M145.59M232M
Effect of Forex Changes4.84M(1.03M)445K1.24M11.08M
Net Change in Cash(19.13M)183K(59.82M)69.65M14.17M
Free Cash Flow(48.16M)(45.49M)(82.15M)(86.26M)(101.22M)

Inventiva S.A.

NASDAQ:IVA

Intrinsic Alpha fair value

Locked

Current Price

$3.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.